Tenecteplase detailed information

Tenecteplase detailed information

Clinical data
ATC code	B01AD11 (WHO)
Identifiers
IUPAC name Human tissue plasminogen activator
CAS Number	105857-23-6
DrugBank	BTD00019
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C2561H3919N747O781S40
Molar mass	58951.2 g/mol

WikiDoc Resources for Tenecteplase detailed information
Articles
Most recent articles on Tenecteplase detailed information Most cited articles on Tenecteplase detailed information Review articles on Tenecteplase detailed information Articles on Tenecteplase detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Tenecteplase detailed information Images of Tenecteplase detailed information Photos of Tenecteplase detailed information Podcasts & MP3s on Tenecteplase detailed information Videos on Tenecteplase detailed information
Evidence Based Medicine
Cochrane Collaboration on Tenecteplase detailed information Bandolier on Tenecteplase detailed information TRIP on Tenecteplase detailed information
Clinical Trials
Ongoing Trials on Tenecteplase detailed information at Clinical Trials.gov Trial results on Tenecteplase detailed information Clinical Trials on Tenecteplase detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Tenecteplase detailed information NICE Guidance on Tenecteplase detailed information NHS PRODIGY Guidance FDA on Tenecteplase detailed information CDC on Tenecteplase detailed information
Books
Books on Tenecteplase detailed information
News
Tenecteplase detailed information in the news Be alerted to news on Tenecteplase detailed information News trends on Tenecteplase detailed information
Commentary
Blogs on Tenecteplase detailed information
Definitions
Definitions of Tenecteplase detailed information
Patient Resources / Community
Patient resources on Tenecteplase detailed information Discussion groups on Tenecteplase detailed information Patient Handouts on Tenecteplase detailed information Directions to Hospitals Treating Tenecteplase detailed information Risk calculators and risk factors for Tenecteplase detailed information
Healthcare Provider Resources
Symptoms of Tenecteplase detailed information Causes & Risk Factors for Tenecteplase detailed information Diagnostic studies for Tenecteplase detailed information Treatment of Tenecteplase detailed information
Continuing Medical Education (CME)
CME Programs on Tenecteplase detailed information
International
Tenecteplase detailed information en Espanol Tenecteplase detailed information en Francais
Business
Tenecteplase detailed information in the Marketplace Patents on Tenecteplase detailed information
Experimental / Informatics
List of terms related to Tenecteplase detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tenecteplase is an enzyme used as a thrombolytic drug.

Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.

Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. It binds to the fibrin component of the thrombus (blood clot) and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus. Tenecteplase has a higher fibrin specificity and greater resistance to inactivation by its endogenous inhibitor (PAI-1) compared to native t-PA.

Tenecteplase is indicated in thrombolytic treatment of the acute phase of myocardial infarction (AMI) for reduction of mortality associated with AMI. Treatment should be initiated as soon as possible after the onset of AMI symptoms.

External links

• Template:MedlinePlusDrugInfo
• Gurbel P, Hayes K, Bliden K, Yoho J, Tantry U (2005). "The platelet-related effects of tenecteplase versus alteplase versus reteplase". Blood Coagul Fibrinolysis. 16 (1): 1–7. PMID 15650539.CS1 maint: Multiple names: authors list (link)
• Melzer C, Richter C, Rogalla P, Borges A, Theres H, Baumann G, Laule M (2004). "Tenecteplase for the treatment of massive and submassive pulmonary embolism". J Thromb Thrombolysis. 18 (1): 47–50. PMID 15744554.CS1 maint: Multiple names: authors list (link)
• Ohman E, Van de Werf F, Antman E, Califf R, de Lemos J, Gibson C, Oliverio R, Harrelson L, McCabe C, DiBattiste P, Braunwald E (2005). "Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial". Am Heart J. 150 (1): 79–88. PMID 16084152.CS1 maint: Multiple names: authors list (link)
• De Luca G, Suryapranata H, Chiariello M (2005). "Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary". Evid Based Cardiovasc Med. 9 (4): 284–7. PMID 16380055.CS1 maint: Multiple names: authors list (link)
• "Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial". Lancet. 367 (9510): 569–78. 2006. PMID 16488800.
• Bozeman W, Kleiner D, Ferguson K (2006). "Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions". Resuscitation. 69 (3): 399–406. PMID 16563599.CS1 maint: Multiple names: authors list (link)
• Hull J, Hull M, Urso J, Park H (2006). "Tenecteplase in Acute Lower-leg Ischemia: Efficacy, Dose, and Adverse Events". J Vasc Interv Radiol. 17 (4): 629–36. PMID 16614145.CS1 maint: Multiple names: authors list (link)

Template:WikiDoc Sources